BHVN
Price
$14.09
Change
-$0.65 (-4.41%)
Updated
Jun 27 closing price
Capitalization
1.44B
36 days until earnings call
SYRE
Price
$15.22
Change
-$0.80 (-4.99%)
Updated
Jun 27 closing price
Capitalization
918.58M
31 days until earnings call
Interact to see
Advertisement

BHVN vs SYRE

Header iconBHVN vs SYRE Comparison
Open Charts BHVN vs SYREBanner chart's image
Biohaven
Price$14.09
Change-$0.65 (-4.41%)
Volume$2.91M
Capitalization1.44B
Spyre Therapeutics
Price$15.22
Change-$0.80 (-4.99%)
Volume$2.21M
Capitalization918.58M
BHVN vs SYRE Comparison Chart in %
Loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. SYRE commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a Buy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (BHVN: $14.09 vs. SYRE: $15.22)
Brand notoriety: BHVN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 126% vs. SYRE: 393%
Market capitalization -- BHVN: $1.44B vs. SYRE: $918.58M
BHVN [@Biotechnology] is valued at $1.44B. SYRE’s [@Biotechnology] market capitalization is $918.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both BHVN and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • BHVN’s TA Score: 3 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than BHVN.

Price Growth

BHVN (@Biotechnology) experienced а -2.56% price change this week, while SYRE (@Biotechnology) price change was +1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

BHVN is expected to report earnings on Aug 04, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($1.44B) has a higher market cap than SYRE($919M). SYRE YTD gains are higher at: -34.622 vs. BHVN (-62.276). SYRE has higher annual earnings (EBITDA): -214.36M vs. BHVN (-914.78M). SYRE has more cash in the bank: 565M vs. BHVN (323M). SYRE has less debt than BHVN: SYRE (0) vs BHVN (35.5M). BHVN (0) and SYRE (0) have equivalent revenues.
BHVNSYREBHVN / SYRE
Capitalization1.44B919M157%
EBITDA-914.78M-214.36M427%
Gain YTD-62.276-34.622180%
P/E RatioN/A1.68-
Revenue00-
Total Cash323M565M57%
Total Debt35.5M0-
FUNDAMENTALS RATINGS
BHVN vs SYRE: Fundamental Ratings
BHVN
SYRE
OUTLOOK RATING
1..100
6650
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9364
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHVN's Valuation (53) in the Pharmaceuticals Major industry is in the same range as SYRE (75). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

BHVN's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

SYRE's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as BHVN (93). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

SYRE's P/E Growth Rating (84) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNSYRE
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
N/A
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 12 days ago
75%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEIFX22.990.12
+0.52%
Federated Hermes Equity Income A
CBLCX53.490.18
+0.34%
Columbia Balanced C
CFMVX23.920.06
+0.25%
Commerce MidCap Value
PGRTX15.000.02
+0.13%
Principal SmallCap Growth I Instl
JSJIX16.27-0.01
-0.06%
JHancock Small Cap Dynamic Growth I

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
-4.41%
SYRE - BHVN
51%
Loosely correlated
-4.99%
BEAM - BHVN
51%
Loosely correlated
-1.98%
CGON - BHVN
50%
Loosely correlated
-0.46%
RVMD - BHVN
47%
Loosely correlated
-1.52%
OCUL - BHVN
47%
Loosely correlated
-2.54%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.99%
CGON - SYRE
57%
Loosely correlated
-0.46%
BEAM - SYRE
55%
Loosely correlated
-1.98%
IMNM - SYRE
54%
Loosely correlated
-0.23%
APGE - SYRE
53%
Loosely correlated
N/A
XNCR - SYRE
53%
Loosely correlated
-3.10%
More